The correlation between serum 25 hydroxyvitamin D levels and readmission in patients with chronic aplastic anemia
10.3760/cma.j.cn431274-20230322-00385
- VernacularTitle:血清25羟基维生素D水平与慢性再生障碍性贫血患者再住院的相关性
- Author:
Xue LI
1
;
Yuhu FENG
Author Information
1. 安徽医科大学附属阜阳人民医院血液内科，阜阳 236000
- Keywords:
Anemia, aplastic;
25-hydroxyvitamin D;
Patient readmission
- From:
Journal of Chinese Physician
2024;26(2):213-217
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the correlation between serum 25 hydroxyvitamin D [25(OH)D] levels and readmission in patients with chronic aplastic anemia (AA).Methods:A total of 105 patients with chronic AA who were hospitalized at the Fuyang People′s Hospital Affiliated to Anhui Medical University from January 2020 to December 2022 were selected. The serum 25(OH)D level was measured using chemiluminescence method, and it was divided into low value group and high value group based on the average value. We compared the clinical data differences between two groups of patients, used logistic multivariate analysis to identify the risk factors for readmission in chronic AA patients, and used the Kaplan Meier method to plot curves to compare the differences in readmission rates and readmission intervals between the two groups.Results:The difference in the interval between readmission between patients in the low value group (<19.39 ng/ml) and those in the high value group (≥19.39 ng/ml) was statistically significant [(2.61±1.03)months vs (3.27±1.32)months, P<0.05]. A higher level of serum 25(OH)D was a protective factor in reducing the risk of readmission ( OR: 0.739; 95% CI: 0.569-0.962) and prolonging the interval between readmission (Log Rank=0.004, Breslow=0.01, Tarone-Ware=0.005; P<0.05) in chronic patients, while long course of illness was a risk factor for readmission ( OR=3.432, P=0.006). Patients in the low value group who had accumulated the use of vitamin D supplements for ≥3 weeks had a significantly longer interval between readmission ( P<0.001). Conclusions:Abnormal reduction of serum 25(OH)D levels can shorten the interval between readmission and increase the risk of readmission in chronic AA patients.
